Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye (PEMDAC)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02697630 |
Recruitment Status :
Completed
First Posted : March 3, 2016
Last Update Posted : December 8, 2023
|
Sponsor:
Vastra Gotaland Region
Collaborators:
Merck Sharp & Dohme LLC
Syndax Pharmaceuticals
Information provided by (Responsible Party):
Vastra Gotaland Region
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | January 31, 2023 |
Actual Study Completion Date : | January 31, 2023 |
Publications of Results: